Kraken introduced DeFi Earn on January 26, enabling users to access decentralized finance yields of up to 8% APY through three automated vault strategies withoutKraken introduced DeFi Earn on January 26, enabling users to access decentralized finance yields of up to 8% APY through three automated vault strategies without

Kraken to Offer Easy DeFi Experience Powered by Ink, Up to 8% APY

2026/01/27 02:08
2 min read

Kraken rolled out DeFi Earn on Jan. 26, offering users a straightforward way to access decentralized finance yields directly in the Kraken app.

According to official communication from a thread on X and Kraken’s DeFi Earn landing page, users deposit cash or stablecoins, which convert to USDC if needed, then select one of three vault strategies: Balanced, High, or Advanced, offering up to 8% APY. The system automatically allocates funds to lending protocols and rewards accrue without further input.

Notably, the feature relies on embedded wallet infrastructure from Privy, eliminating the need for seed phrases or manual transaction signatures. Vaults are built by Veda Labs on the Ink Network—Kraken’s Ethereum  Layer 2 (L2)—with risk oversight from Chaos Labs and Sentora.

Rewards come from actual borrower demand on known DeFi platforms like Aave, Morpho, Tydro, and Sky Ecosystem, a FAQ section in the landing page explains. There are no token subsidies or temporary boosts. Kraken charges a 25% fee on rewards only. Moreover, withdrawals are typically instant, though brief delays can occur if protocol liquidity is low.

DeFi Earn launches in 48 states of the US, Canada, and the European Economic Area, with more regions planned.

Kraken Moves Into DeFi

The product fits into Kraken’s broader push to combine traditional and decentralized finance. In November 2025, the exchange introduced Auto Earn for simple passive yields on crypto holdings with no lock-ups, as covered by Coinspeaker. Earlier moves include commission-free stock and ETF trading in select US states in April 2025 and the Krak Card for unified crypto banking in December.

Kraken also continues development on its own blockchain, Ink, originally announced for expanded DeFi access.

Data from DefiLlama shows the L2 is already ranking 14th by TVL, featuring side by side with leading L1 blockchains like Sui, which ranks 13th. Ink currently goes with $534 million in total value locked and has $595 million in stablecoin market cap, with a 43% dominance by Circle’s USDC.

Ink DeFi data as of January 26, 2026 | Source: DeFiLlama

Ink DeFi data as of January 26, 2026 | Source: DeFiLlama

Overall, the ecosystem went through significant growth in early October last year, backed by Kraken’s user base and market share. This new product could boost this growth even more with easier onboarding and a better user experience.

next

The post Kraken to Offer Easy DeFi Experience Powered by Ink, Up to 8% APY appeared first on Coinspeaker.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26